AVTE News and Press, Aerovate Therapeutics Inc. From 04/01/22

Gainers: Weidai (WEI) +68%. Manning & Napier (MN) +41%. Chicken Soup for the Soul Entertainment (CSSE) +28%. Hudson Capital (HUSN) +26%. Guardforce AI (GFAI) +19%. U.S. Xpress Enterprises (USX) +20%. Blackboxstocks (BLBX) +17%. Takung Art (TKAT) +17%. Borr Drilling (BORR) +17%. Clever Lea...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Aerovate Therapeutics press release (NASDAQ:AVTE): FY GAAP EPS of -$1.87 misses by $0.29. Cash, cash equivalents and short-term investments totaled $167.4 million as of December 31, 2021. For further details see: Aerovate Therapeutics GAAP EPS of -$1.87 misses by $0.29

Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021 Received FDA guidance in April 2021 that our Phase 2b/Phase 3 trial could support an NDA submission based on change in six minute walk distance as the primary endpoi...

WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, today announced that Company management w...

Gainers: Adagio Therapeutics (NASDAQ:ADGI) +113%. Aptose Biosciences  (NASDAQ:APTO) +30%. Calliditas Therapeutics  (NASDAQ:CALT) +28%. Kaixin Auto Holdings (NASDAQ:KXIN) +27%. Insignia Systems (NASDAQ:ISIG) +27%. Losers: Bakkt Holdings (NYSE:BKKT) -33%....

Gainers: Adagio (NASDAQ:ADGI) +101%. Kaixin (NASDAQ:KXIN) +34%. Calliditas (NASDAQ:CALT) +25%. Euro Tech Holdings (NASDAQ:CLWT) +19%. Mechel (NYSE:MTL) +17%. Processa (NASDAQ:PCSA) +17%. Versus Systems (NASDAQ:VS) +17%. Assertio (NASDAQ:ASRT) +17%. Zai Lab (NASDAQ:ZLAB) +17%. Petros Pharmaceu...

Aerovate Therapeutics (AVTE +21.1%) has added more than a fifth in value on below-average volume after the biotech marked a key milestone in its post-IPO operations with the start of a clinical trial for its only product candidate, AV-101. The Phase 2b/Phase 3 IMPAHCT trial is designed to eva...

WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, today announced the initiation of its I ...

Aerovate Therapeutics (NASDAQ:AVTE): Q3 GAAP EPS of -$0.26 in-line. Cash and cash equivalents of $180.87M Shares -10.24%. Press Release For further details see: Aerovate Therapeutics EPS in-line